The replication of human immunodeficiency retroviruses involves a complex series of events that is regulated at both transcriptional and posttranscriptional levels. The tat gene product is a potent trans-activator of viral transcription and therefore an attractive target for the development of antiviral drugs. Tat-defective HIV-1 proviral DNA clones have been shown previously to be replication defective. In this study, we report that tat-defective HIV-1 and HIV-2 viral DNA transfected into U937 cells can direct efficient viral replication in the presence of transcriptional stimulators such as TNF-a and PMA. In MT-4 cells, tat-defective HIV-1 can replicate without any stimulation. The viruses recovered from MT-4 cells remained tat defective defined by their inability to infect T cell lines (e.g., Molt 4/8) although replication could be rescued with cytokines. Limited replication was observed in primary mononuclear cells. Furthermore, we showed that Ro 24-7429, a potent tat antagonist and antiviral compound, failed to suppress HIV-1 replication in TNF-a-stimulated T cells. These results have important implications for targeting tat as a therapeutic strategy for AIDS. (J. Clin. Invest. 1995. 95:328-332.)
Introduction
Human immunodeficiency viruses contain several regulatory genes, among which tat encodes an early protein that transactivates viral gene expression. The Tat protein binds a cis-acting RNA element (TAR), located downstream of the transcriptional initiation site in the viral long terminal repeat (LTR) (1) . The mechanism of tat trans-activation has been suggested to be at the level of increasing transcriptional initiation or elongation (1, 2) . Previous studies indicated that tat is essential for HIV replication (3) (4) (5) (6) . Additional regulatory elements responsive to cellular transcription factors are also present in the LTR, e.g., the core promoter elements SP-1 and TATA (7) , and enhancer elements, including the nuclear factor KB, (NF-kB) binding site (8) which is required for activation of virus expression in response to external stimulation such as immune activation. For example, TNF-a and PMA activate HIV expression via the uncoupling of NF-kB from its cytoplasmic inhibitor I-kB (8, 9) . The inductive effect of TNF-a on HIV expression has been shown in a variety of cell types and its molecular mechanism of action is one of the best examples of functional interactions between HIV and the immune system. TNF-a is of particular interest and relevance because of previous reports of elevated plasma levels of circulating TNF-a in HIV-1 -infected individuals (10, 11 ) and increased TNF-a production de novo by freshly isolated PBMC, circulating monocytes, tissue macrophages, and B lymphocytes (12, 13) . Therefore, the potential stimulatory role of TNF-a in HIV replication and disease progression warrants further examination.
Because of prior evidence for the essential role of tat in HIV replication in vitro several antiviral strategies have been aimed at inhibiting tat function. It has been shown that Tatsequestering systems such as a TAR decoy RNA can inhibit replication of both HIV-1 and HIV-2 (14) . Similarly, the benzodiazepine compound Ro 5-3335 [7-chloro-5-(2pyrryl) -3H-1,4-benzodiazepin 2(H)-one] and its derivatives, Ro 24-7429, are potent antiviral drugs first identified by screening for tat inhibition (15, 16) . Molecular mechanism of action of these two compounds is not completely understood but probably involves cellular factors that cooperate in tat action (17) .
Treatment of cells acutely or chronically infected with HIV-1 or HIV-2 in the presence of 0.3-1 MM of Ro 24-7429 significantly reduced expression of viral RNA and antigen in vitro (15, 16) . In this study, we showed that the inhibitory effects of the tat antagonist can be overridden by TNF-a. Furthermore, tat-defective HIV can replicate in the presence of stimulation by TNF-a and PMA in the U937 cells and without any stimulation in the MT-4 cells. Our results suggest that the requirement of tat may be bypassed by immune activation and cytokine induction, which are common occurrences in HIV-infected individuals.
inactivated fetal bovine serum, 2 mM L-glutamine, and 50 U/ml recombinant IL-2. PBMC (6 x 106 cells) were infected with 50,000 ng of HIV-1NL43 (tat-) and HIV-ILAI supernatant as described above. Supernatant was collected at designated time points and used for titration experiments and viral antigen (p24) measurements (Coulter Immunology, Hialeah, FL).
Plasmids, transfections, and choline-o-acetyl transferase (CAT) assays. HIV clones with defective tat gene used in the study were: HIV-IHXB (,t,-) obtained from Dr. M. Feinberg (University of California, San Francisco) was made by deleting the second nucleotide in the tat initiation codon and by inserting a synthetic linker containing stop codons (18) . An HIV-INL43(I) provirus containing a TAG codon at amino acid position 9 (glutamic acid) of the tat reading frame was constructed previously by mutagenesis at an subclone; pTS9M (19) . Tat-defective
HIV-2KR
was derived from the infectious clone HIV-2KR (20) . The HIV-2KR(tat-) mutant was engineered by deleting the first 18 nucleotides of the first coding exon of tat, including the AUG codon. HIV-IHX13.2 and HIV-2KR were used as controls). Infectious HIV-2KR was generated by cotransfection with two DNA plasmids containing the 5' and 3' halves of the viral genome, respectively. Equal amounts of each plasmid were linearized with the restriction enzyme SacI and then ligated before transfection. The HIV-2 CAT plasmid contained HIV-2 ST LTR sequences linked to the CAT reporter gene (21) . Approximately 1.4 x 106 of U937 cells were transfected with designated plasmids using the DOTAP (Boehringer Mannheim Biochemicals, Indianapolis, IN) while 1 x 106 cells of designated T cell lines were transfected with Lipofectin (GIBCO BRL, Gaithersburg, MD). 24 h after transfection, the designated cultures were treated with either TNF-a (Promega Corp.), or PMA (Sigma Chemical Co.). For CAT assays, -1.2 X 106 cells were transfected using DOTAP and harvested 72 h later. Cell extracts were prepared for analysis using the CAT-ELISA system (both from Boehringer Mannheim Biochemicals) and 1/5 of the extract was used in the assay. After the standardized assay protocol, absorbance was measured at 405 nm and the amount of expressed protein was calculated from a standard curve.
Results
Replication of Tat-defective viruses in the presence of TNF-a and PMA. To verify that tat is indeed nonfunctional in the tat mutant proviral DNA clones, we cotransfected them with an HIV-2 LTR-CAT reporter gene and measured CAT production by an ELISA assay. U937 cells, cotransfected with the reporter construct and two different HIV-1 tat-defective clones, HIV-IHXB-2 (tat-) and HIV-1INL 4.3 (tw-), as well as HIV-2KR (ta,_), did not produce detectable amounts of CAT ( Fig. 1 A) . In contrast, transfection of wild-type HIV-lHXB12 and HIV-2 proviruses induced the synthesis of substantial amounts of CAT as expected. We then transfected the same proviral DNA clones into U937 cells and monitored virus replication by the antigen capture assay for capsid proteins (Fig. 1 B) . In cells not treated with phorbol esters, no virus expression was detected for the HIV-2KR (t) (lane 3), although virus production was rescued by providing a tat-cDNA in trans (lane 4), as previously reported (5, 22) . Upon stimulation with PMA, virus production was enhanced for the wild-type virus; but more importantly, virus production for the HIV-2KR (ta-) was now comparable to wildtype virus without stimulation (lane S vs. lane 1), and was not diminished in the presence of Ro 24-7429, a potent tat inhibitor (not shown). Tat-defective HIV-1 clones [1HV-lW12() (tat-) and HIV-1NL 4.3 (t, ] also responded to stimulation by PMA as well as TNF-a (Fig. 1 C) . Co-stimulation of cells with TNFa and IL-6 further increased the amount of viral antigen production by 40% (data not shown). The synergistic effects of these cytokines on wild-type HIV-1 replication have been described previously (23). (Fig. 2 A) . MT-4 is an HTLV-l-transformed cell line also known to produce high levels of NF-kB (24 (Fig. 3) . A concentration of 10 jM Ro 24-7429 was used, which is 15-fold higher than the 50% inhibitory concentration of this compound in CEM cells (16) . This concentration of Ro 24-7429 exhibited a potent antiviral effect during the 7-d assay period but little cellular toxicity, consistent with previous reports. However, adding TNF-a to the culture significantly reduced the antiviral effect of Ro 24-7429. In the absence of Ro 24-7429, TNF-a slightly accelerated virus replication. These results suggested that stimulation of viral replication with physiological levels of TNF-a can override the requirement for tat. Antiviral effect of Ro 24-7429 was also not observed with replication of HIV-2KR (tat-) in the presence of PMA (data not shown).
To confirm that viruses recovered from TNF-a-stimulated cultures in the presence of Ro 24-7429 were infectious, we performed titration experiments of the culture supernatant on MT-2 cells. As can been seen in Table I 106.0
Culture supernatant at day 6 postinfection was used to measure infectious titer in a titration assay using MT-2 cells involving a series of progressive dilution of virus supernatant (32) . The results are expressed in tissue infectious dose (TCID50) of highest dilution of virus suspension that infects 50% of the culture as measured by visible virus-induced cytopathic effects (CPE).
were comparable in the presence or absence of Ro 24-7429 and with TNF-a, as assayed by syncytium induction. Without TNFa, Ro 24-7429 suppressed virus infectivity by 103 50% tissue culture infectious dose.
Discussion
HIV-1 tat-defective proviruses have been frequently identified in the viral quasi species by direct amplification and sequencing from primary lymphocytes of patients (25) . Tat-defective viruses show restricted replication in vitro, but can be passaged in tat-expressing cell lines (26) . A recent study observed that two identical inactivating mutations in the first exon of tat were present in a high percentage (50%) of proviruses in the PBMC of an HIV-1, infected asymptomatic individual (27) . These results suggest that tat-defective genomes could propagate by viral replication and infectious spread in vivo.
The most important cis regulatory elements in the HIV LTRs are TAR, Sp-1, and NF-kB elements to which viral and cellular transactivators bind. Activation of viral replication with TNF-a occurs via induction of nuclear factor binding to the NF-kB sites, present as two tandem copies in the LTR (28) . Maximal induction of viral transcription can be achieved by cooperative activation by NF-kB proteins and Tat (29) . NF-kB binding sites are not required for the replication of HIV in human T lymphocytes as long as the three Sp-l binding sites are retained in the LTR (24) . The viruses deleted in Sp-l sites but retaining NF-kB elements replicated efficiently in cells and PHA-stimulated PBLs, which express high levels of NF-kB proteins, but poorly in the CEM cells unless TNF-a was added (30). These results suggest that NF-kB activity may functionally compensate for Sp-l in activating HIV replication. A recent report showed that a T cell line CEMR7/neo with a stably integrated tat-defective provirus expressed low levels of virus after stimulation with TNF-a (31) . However, they observed high levels of gag precursor Pr55gag and low levels of mature, processed proteins like p24, and concluded that TNFa may play a role in initiating limited early transcription of HIV-1 before tat expression, but could not replace the potent transcriptional and posttranscriptional effects of tat for efficient virus expression. Our data, in contrast, showed that tat-defective viruses can replicate to near wild-type levels in the presence of TNF-a or PMA after transient transfection into U937 cells, or in MT-4 cells without stimulation. It is noteworthy that virus replication in MT-4 was previously found to be refractory to the tat antagonist (32) Elevated production of cytokines may be an important component of the immunopathogenesis and disease progression of HIV infection (33) (34) (35) . TNF-a and other inflammatory cytokines have been reported to be present at elevated levels in the plasma or cerebrospinal fluid of HIV-infected individuals (10, 36, 37) . Peripheral blood lymphocytes and monocytes from infected patients may also spontaneously produce high levels of TNF-a (12, 13) . Furthermore, increased amounts of transmembrane TNF-a have been noted on T and B cells (35, 38) and have been implicated in the polyclonal B cell activation of these patients (39) . The elevated levels of cytokines (TNF-a, IL-1, IL-6), in addition to exerting systemic effects on the host (fever, cachexia) could also contribute to activating virus production, including production from tat-defective genomes.
Because of prior evidence for the essential role of tat in HIV replication in vitro, many antiviral strategies are aimed at inhibiting tat function. Our results indicate that activating the virus through the NF-kB pathway in the presence of a tat inhibitor can significantly rescue viral replication. Therefore, such inhibitors may not be effective in vivo since immune activation and cytokine induction are common occurrences in infected individuals. This may explain in part the discouraging results of a phase clinical trial with this same tat antagonist 7429 (40) . The HIV LTR contains multiple protein-binding sites that have variable importance in different cell types and may functionally complement each other. Therefore, therapy aiming to inhibit viral transcription should include inhibitors of both tat transactivation and transactivation through NF-kB or other cellular factors. Two compounds through to inhibit HIV replication in vitro through inhibition of the NF-kB pathway are pentoxyfylline (41, 42) and thalidomide (43) . Pentoxyfylline inhibits NF-kB interactions with its response elements (42) , while thalidomide inhibits TNF-a mRNA expression (43) . Additionally, selective blocking of other cytokines could have important implications in treatment of HIV disease.
